We have been activated in this trial that evaluates the safety of an innovative compound (antisense oligonucleotide) that aims to inhibit the activity of the LRKK2 gene and reduce the formation of alfasynuclein.

Compartir:
CategoryParkinson

No dude en llamarnos        1-+34 935 656 000